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Editors: Anton N. Sidawy and Bruce A. PerlerFinal operative and midterm results of the European experience in the
RELAY Endovascular Registry for Thoracic Disease (RESTORE) study
Vincent Riambau, Burkhart Zipfel, Gioacchino Coppi, Martin Czerny,
Domenico G. Tealdi, Carlo Ferro, Roberto Chiesa, Carlo Sassi, Herve
Rousseau, Sergio Berti, on behalf of the RELAY Endovascular Registry for
Thoracic Disease RESTORE Investigators
Purpose: Thoracic endovascular aortic repair is increasingly becoming the
standard treatment of many thoracic aortic pathologies. New reliable and
accurate stent grafts are emerging to widen the endovascular treatment
options. We report the results of RELAY (Bolton Medical, Barcelona, Spain)
in the large RELAY Endovascular Registry for Thoracic Disease (RESTORE)
European registry.
Methods: RESTORE is a multicenter, prospective European registry involving
22 centers in seven European countries. The RELAY device is composed of
a stent graft (self-expanding nitinol stents and a polyester vascular graft)
and a delivery device specifically designed for the thoracic aorta. Included
were acute and elective patients presenting with a variety of pathologies
(aneurysms, dissections, ulcerations, intramural hematomas, pseudoaneur-
ysms) and lesions in different aortic and anatomic locations (ascending,
arch, descending and thoracoabdominal).
Results: The registry enrolled 304 patients from April 2005 to January 2009.
All-cause mortality at 30 days was 7.2%. Freedom from all cause mortality
and freedom from device- and procedure-related mortality at 2 years were
78.5% and 95.9%, respectively. An average of 1.26 graft components were
used per patient, with a technical success of 97.7% irrespective of the
etiology. Early endoleak rate was 4.6%. Perioperatively, stroke and para-
plegia were registered in 1.6% and 2.0%, respectively.
Conclusions: The results of RESTORE support the safety of thoracic endovas-
cular aortic repair with the RELAY stent graft, even in acute and complicated
situations. The device was highly efficient in angulated aortic anatomies,
with acceptable mortality and a low rate of neurologic complications.Initial clinical experience with a sac-anchoring endoprosthesis for aortic
aneurysm repair
Carlos E. Donayre, Christopher K. Zarins, Dainis K. Krievins, Andrew Holden,
Andrew Hill, Carlos Calderas, Jaime Velez, Rodney A. White
Objective: All current aortic endografts depend on proximal and distal fixa-
tion to prevent migration. However, migration and rupture can occur, partic-
ularly in patients with aortic necks that are short or angulated, or both. We
present our initial clinical experience with a new sac-anchoring endoprosth-
esis designed to anchor and seal the device within the aneurysm sac.
Methods: The initial worldwide experience using a new endoprosthesis for the
treatment of aortic aneurysms (Nellix Endovascular, Palo Alto, Calif) was re-
viewed. The endoprosthesis consists of dual balloon-expandable endoframes
surrounded by polymer-filled endobags designed to obliterate the aneurysm
sac and maintain endograft position. Clinical results and follow-up contrast
computed tomography (CT) scansat30days and6and12monthswere reviewed.* Full articles available online at www.jvascsurg.org
1078e5884/$36.00
doi:10.1016/S1078-5884(11)00048-7Results: The endograft was successfully deployed in 21 patients with infra-
renal aortic aneurysms measuring 5.7  0.7 cm (range, 4.3-7.4 cm). Two
patients with common iliac aneurysms were treated with sac-anchoring
extenders that maintained patency of the internal iliac artery. Infusion of
71  37 mL of polymer (range, 19-158 mL) into the aortic endobags resulted
in complete aneurysm exclusion in all patients. Mean implant time was 76 
35 minutes, with 33  17 minutes of fluoroscopy time and 180  81 mL of
contrast; estimated blood loss was 174  116 mL. One patient died during
the postoperative period (30-day mortality, 4.8%), and one died at 10 months
from non-device-related causes. During a mean follow-up of 8.7  3.1
months and a median of 6.3 months, there were no late aneurysm-or
device-related adverse events and no secondary procedures. CT imaging
studies at 6 months and 1 year revealed no increase in aneurysm size, no
device migration, and no new endoleaks. One patient had a limited proximal
type I endoleak at 30 days that resolved at 60 days and remained sealed. One
patient has an ongoing distal type I endoleak near the iliac bifurcation, with
no change in aneurysm size at 12 months.
Conclusion: Initial clinical experience with this novel intrasac anchoring
prosthesis is promising, with successful aneurysm exclusion and good
short-term results. This new device platform has the potential to address
the anatomic restrictions and limitations of current endografts. Further
studies with a longer follow-up time are needed.Surgeon case volume, not institution case volume, is the primary
determinant of in-hospital mortality after elective open abdominal
aortic aneurysm repair
James T. McPhee, William P. Robinson III, Mohammad H. Eslami, Elias J.
Arous, Louis M. Messina, Andres Schanzer
Objective: Studies analyzing the effects of volume on outcomes after
abdominal aortic aneurysm (AAA) repair have primarily centered on institu-
tional volume and not on individual surgeon volume. We sought to determine
the relative effects of both surgeon and institution volume on mortality after
open and endovascular aneurysm repair (EVAR) for intact AAAs.
Methods: The Nationwide Inpatient Sample (2003-2007) was queried to
identify all patients undergoing open repair and EVAR for nonruptured
AAAs. To calculate surgeon and institution volume, 11 participating states
that record a unique physician identifier for each procedure were
included. Surgeon and institution volume were defined as low (first quin-
tile), medium (second, third, or fourth quintile), and high (fifth quintile).
Stratification by institution volume and then by surgeon volume was per-
formed to analyze the primary endpoint: in-hospital mortality. Multivari-
able models were used to evaluate the association of institution and
surgeon volume with mortality for open repair and EVAR, controlling for
potential confounders.
Results: During the study period, 5972 open repairs and 8121 EVARs were
performed. For open AAA repair, a significant mortality reduction was asso-
ciated with both annual institution volume (low <7, medium 7-30, and high
>30) and surgeon volume (low 2, medium 3-9, and high >9). High surgeon
volume conferred a greater mortality reduction than did high institution
volume. When low and medium volume institutions were stratified by
surgeon volume, mortality after open AAA repair was inversely proportional
Abstracts 439to surgeon volume (8.7%, 3.6%, and 0%; P < .0001, for low, medium, and
high-volume surgeons at low-volume institutions; and 6.7%, 4.8%, and
3.3%; P = .02, for low, medium, and high-volume surgeons at medium-volume
institutions). High-volume institutions stratified by surgeon volume demon-
strated the same trend (5.1%, 3.4%, and 2.8%), but this finding was not statis-
tically significant (P = .57). Multivariable analysis was confirmatory: low
surgeon volume independently predicted mortality (odds ratio [OR], 2.0;
95% confidence interval [CI], 1.3-3.1; P < .001); low institution volume did
not (P = .1). For EVAR, neither institution volume nor surgeon volume influ-
enced mortality (univariate or multivariable).
Conclusion: The primary factor driving the mortality reduction associated
with case volume after open AAA repair is surgeon volume, not institution
volume. Regionalization of AAAs should focus on open repair, as EVAR
outcomes are equivalent across volume levels. Payers may need to re-eval-
uate strategies that encourage open AAA repair at high-volume institutions if
specific surgeon volume is not considered.Carotid endarterectomy in the acute phase of crescendo cerebral
transient ischemic attacks is safe and effective
Guy Leseche, Jean-Marc Alsac, Yves Castier, Francis Fady, Philippa C.
Lavallee, Mikael Mazighi, Pierre Amarenco
Objective: To document the 30- and 90-day outcomes in patients with severe
internal carotid artery stenosis who underwent carotid endarterectomy in the
acute phase of crescendo cerebral transient ischemic attacks (CcTIAs).
Methods: From January 2003 to December 2009, data from patients suffering
CcTIAs with an ipsilateral severe internal carotid artery stenosis and consec-
utively operated in our department were prospectively collected. CcTIA
patients operated in the acute phase were those who had experienced two
cerebral TIAs and had been consecutively operated within 2 weeks of their
first-ever TIA. Clinical assessment was by the vascular neurologist. Duplex
ultrasonography was initially used for the diagnosis of severe (>70%) ipsilat-
eral internal carotid artery and further assessed by magnetic resonance angi-
ography and/or computed tomography angiography. Brain damage was
assessed by magnetic resonance imaging or at default computed tomography
scan. Perioperative medical treatment and operative techniques were stan-
dardized. Stroke, death, and major cardiac events were analyzed.
Results: Sixty-four patients sustained a median of four cerebral TIAs.
Median delay to surgery from initial examination was 5 days. The mean
degree of internal carotid artery stenosis was 87.9%. Of the 55 patients
who had magnetic resonance imaging with diffusion-weighted imaging, 43
(78%) patients had new acute infarction in an area that corresponded to
the clinical symptoms. All patients received antiplatelet therapy and statin
during the intervening period. All patients underwent conventional carotid
endarterectomy (CEA) with patch angioplasty (polytetrafluoroethylene).
Fifty-six patients (87.5%) underwent CEA under local anesthesia with two
(3.5%) utilizing selective shunting, and eight patients had general anesthesia
with systematic shunting. From CEA to discharge, all patients had complete
recovery of their unstable clinical syndrome. At discharge and at 1 and 3
months postoperatively, no stroke or death, or major cardiac event occurred
in this series with a 100% complete follow-up.
Conclusions: Short delay between symptom onset and neurological assess-
ment, immediate start of secondary stroke prevention, optimal periopera-
tive medical treatment, and standardized operative techniques enabled
performance of CEA in the acute phase of CcTIAs with low combined risk
of stroke, death, and major cardiac event.
The quality of life in patients after peripheral bypass surgery deteriorates
at long-term follow-up
Eline S. van Hattum, Marco J.D. Tangelder, James A. Lawson, Frans L. Moll,
Ale Algra
Objective: We aimed to study the long-term development of health-related
quality of life (HR-QoL) in patients with peripheral arterial disease after they
underwent peripheral bypass surgery and to evaluate the influence of
adverse vascular events that occurred during follow-up.
Methods: We compared current HR-QoL scores with previous measurements
in patients who participated in the Dutch Bypass and Oral Anticoagulants or
Aspirin (BOA) Study between 1995 and 1998 after they underwent infraingu-
inal bypass surgery. Patients from six centers that contributed most to the
Dutch BOA Study (n = 482) were followed up retrospectively from 1995 up
to 2009.Results: At a mean follow-up of 11 years since BOA randomization, 165 of
the 482 patients were alive of whom 123 (75%) completed the EQ-5D and
RAND-36 questionnaires. Fifty-three patients completed the questionnaires
three times: at BOA entry, at BOA close-out, and at BOA long-term follow-
up. In these patients the HR-QoL scores decreased over time, especially
for the physical health dimension. In comparison with the general popula-
tion, matched for age and gender, the HR-QoL scores at both BOA entry
and long-term follow-up were substantially lower, even if the patient’s graft
was patent and no other vascular events had occurred. The occurrence of an
adverse vascular event worsened the physical health state further.
Conclusions: The physical HR-QoL in patients with peripheral arterial
disease (PAD) after peripheral bypass surgery was highly impaired, indepen-
dent of graft patency, and deteriorated further over time. An adverse
vascular event worsened the physical health state and underlined the impor-
tance of atherosclerotic risk management as well as stimulation of physical
activity in patients with peripheral arterial disease to preserve HR-QoL.A comparison of endovascular revascularization with traditional therapy
for the treatment of acute mesenteric ischemia
Zachary M. Arthurs, Jessica Titus, Mohsen Bannazadeh, Matthew J. Eagleton,
Sunita Srivastava, Timur P. Sarac, Daniel G. Clair
Objectives: Few centers have adopted endovascular therapy for the treat-
ment of acute mesenteric ischemia (AMI). We sought to evaluate the effect
of endovascular therapy on outcomes for the treatment of AMI.
Methods: A single-center, retrospective cohort review was performed on all
consecutive patients with thrombotic or embolic AMI presenting between
1999 and 2008. Patients with mesenteric venous thrombosis, nonocclusive
mesenteric ischemia, and ischemia associated with aortic dissection were
excluded. Demographic factors, preoperative metabolic status, and etiology
were compared. Primary clinical outcomes included endovascular technical
success, operative complications, and in-hospital mortality.
Results: Seventy consecutive patients were identified with AMI (mean age,
64  13 years). Etiology of mesenteric ischemia was 65% thrombotic and
35% embolic occlusions. Endovascular revascularization was the preferred
treatment (81%) vs operative therapy (19%). Successful endovascular treat-
ment was achieved in 87%. Endovascular therapy required laparotomy in
69% vs traditional therapy in 100% (P < .05), with a median 52-cm necrotic
bowel resected (interquartile range [IQR], 11-140 cm) vs 160 cm (IQR, 90-
250 cm; P < .05), respectively. Acute renal failure and pulmonary failure
occurred less frequently with endovascular therapy (27% vs 50%; P < .05
and 27% vs 64%; P < .05). Successful endovascular treatment resulted in
a mortality rate of 36% compared with 50% (P < .05) with traditional therapy,
whereas the mortality rate for endovascular failures was 50%. Endovascular
therapy was associated with improved mortality in thrombotic AMI (odds
ratio, 0.10; 95% confidence interval, 0.10-0.76; P < .05).
Conclusions: Endovascular therapy has altered the management of AMI, and
there are measurable advantages to this approach. Using endovascular therapy
as the primary modality for AMI reduces complications and improves outcomes.
Iliofemoral stenting for venous occlusive disease
Jessica M. Titus, Mireille A. Moise, James Bena, Sean P. Lyden, Daniel G.
Clair
Background: Venous hypertension is a significant cause of patient morbidity
and decreased quality of life. Common etiologies of venous hypertension
include deep venous thrombosis (DVT) or congenital abnormalities resulting
in chronic outflow obstruction. We have implemented an aggressive endo-
vascular approach for the treatment of iliac venous occlusion with angio-
plasty and stenting. The purpose of this study was to determine the
patency rates with this approach at a large tertiary care center.
Materials/Methods: All patients undergoing iliofemoral venous angioplasty
and stenting over a 4-year period were identified from a vascular surgical
registry. Charts were reviewed retrospectively for patient demographics,
the extent of venous system involvement, the time course of the venous
pathology, and any underlying cause. Technical aspects of the procedure
including previous angioplasty or stenting attempts, and presence of collat-
erals on completion venogram were then recorded. Patency upon follow-up
was determined using primarily ultrasound scans; other imaging methods
were used if patency was not clear using an ultrasound scan.
Results: A total of 36 patients (40 limbs) were stented from January 2005
through December 2008. Of these patients, 27 were women (75%). Both
440 Abstractslower extremities were involved in 4 patients. Thrombolysis was performed
in 19 patients (52.8%). Thrombosis was considered acute (<30 days) in 13
patients (38%). The majority of patients who had a recognized underlying
etiology were diagnosed with May-Thurner syndrome (15 patients; 42%). In
9 patients, an etiology was not determined (25%). The mean follow-up time
period in the study population was 10.5 months. One stent in the study
occluded acutely and required restenting. Primary patency rates at 6, 12,
and 24 months were 88% (75.2-100), 78.3% (61.1-95.4), and 78.3% (61.1-
95.4), respectively. Secondary patency rates for the same time frames were
100% (100.0, 100.0), 95% (85.4, 100.0), and 95% (85.4, 100.0). Better
outcomes were seen in stenting for May-Thurner syndrome and idiopathic
causes, whereas external compression and thrombophilia seemed to portend
less favorable outcomes (P < .001). Symptomatic improvement was reported
in 24 of 29 patients (83%) contacted by telephone follow-up.
Conclusion: Iliofemoral venous stenting provides a safe and effective option
for the treatment of iliac venous occlusive disease. Acceptable patency rates
can be expected through short-term follow-up, especially in the case of May-
Thurner syndrome. Further experience with this approach and longer-term
follow-up is necessary. Thrombophilia workup should be pursued aggressively
in this population, and further studies should be undertaken to determine the
optimal length of anticoagulation therapy after stent placement.Ethanol embolotherapy of hand arteriovenous malformations
Hong Suk Park, Young Soo Do, Kwang Bo Park, Dong-Ik Kim, Young Wook Kim,
Myung Joo Kim, Byung Seop Shin, In Wook Choo
Purpose: Ethanol embolotherapy is one of the established methods in the
treatment of extremity arteriovenous malformations (AVMs). The purposeof this study was to report the application of this method to hand AVMs
and to assess retrospectively the therapeutic outcomes and complications.
Patients and Methods: From December 1998 to March 2009, we treated 31
patients with hand AVMs (16 women, 15 men, age range, 5-51 years; mean
age, 27 years). With the patients under general anesthesia, they underwent
staged ethanol embolotherapy (range, 1-11 sessions; mean, 2.8 sessions) by
direct puncture and or intra-arterial approach. Therapeutic outcomes were
evaluated by clinical responses of symptoms and signs, as well as the degree
of devascularization on angiography. We also divided the patients into three
groups according to the extent of involvement: a group involving fingers (n =
14), a group involving fingers and parts of the palm (n = 9), and a group
involving parts of the palm (n = 8) and compared the therapeutic outcomes
and complications among groups.
Results: One patient (3%) was cured, 22 patients (73%) showed improve-
ment, and 7 patients (23%) showed no change or aggravation after the
treatment. One patient was lost to follow-up. Nineteen patients (61%)
had one or more complications, including skin necrosis in 14 patients
(45%), bullae in 7 patients (23%), joint stiffness or contracture in 6 patients
(19%), and transient nerve palsy in 4 patients (13%). All of the complica-
tions were resolved completely after 1 to 8 months’ (average, 3.4 months)
follow-up, except in 2 patients who underwent amputation. According to
the location of AVMs, rates of therapeutic benefit and complications were
93% and 64% in the group involving fingers, 38% and 78% in the group
involving fingers and the palm, and 88% and 38% in the group involving
the palm, respectively.
Conclusion: Ethanol embolotherapy of hand AVMs improves symptoms in
a certain percentage of patients with a relatively high risk of complications.
According to the extent of AVMs, there was a trend toward a higher compli-
cation rate in treatment of AVMs involving fingers and a lower rate of ther-
apeutic benefit in AVMs involving both the fingers and the palm.
